206 - Durable Survival and Updated Safety of TQB2450 plus Anlotinib Maintenance Therapy in Limited-Stage Small Cell Lung Cancer: Extended Follow-Up from a Prospective Phase Ib Trial

11:05am - 11:15am PT

Presenter(s)

Xiangjiao Meng, - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan,